Core Viewpoint - Enwei Pharmaceutical, established in 2005 and listed in 2022, specializes in the pharmaceutical sector with a focus on gynecology, pediatrics, and respiratory medications, holding a notable brand presence in China [1] Financial Performance - For Q3 2025, Enwei Pharmaceutical reported revenue of 637 million yuan, ranking 51st among 69 companies in the industry, with the industry leader, Baiyunshan, generating 61.606 billion yuan [2] - The company's net profit for the same period was 36.5847 million yuan, placing it 46th in the industry, while the top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan [2] Financial Ratios - As of Q3 2025, Enwei Pharmaceutical's debt-to-asset ratio was 27.60%, lower than the industry average of 32.81% [3] - The company's gross profit margin stood at 48.22%, which is below the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.72% to 6,340, while the average number of shares held per shareholder increased by 261.71% to 16,200 [5]
恩威医药的前世今生：2025年三季度营收6.37亿排行业51，净利润3658.47万排46